Biotechnology industry alert provided by U.S. Equity News. Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) will webcast its Quarterly Update Conference Call for the third quarter of 2007 on Wednesday, October 17, 2007 at 5:00 p.m. ET/2:00 p.m. PT. Daniel M. Bradbury, Amylin's President and Chief Executive Officer, will lead the call. On the same date post market, Amylin will release financial results for the third quarter of 2007. The call will be webcast live through Amylin's corporate website and a recording will be made available following the close of the call.
Emergency Disaster Systems, Inc., a subsidiary of U.S. BioDefense, Inc. (OTCBB: UBDE), announces it will be attending "The 2nd Annual National Emergency Preparedness Conference." The conference will be held October 11th - 13th, at the Capital Christian Conference Center and Disaster Exercise Location, Sacramento, CA. Attendees include anyone involved with volunteerism and emergency readiness: volunteers, emergency responders, program coordinators, community organizers, emergency management administrators, and government agencies. U.S. BioDefense, Inc. is a Department of Defense Central Contractor that researches, develops, and commercializes homeland security and leading edge biotechnologies.
Gilead Sciences, Inc. (NASDAQ: GILD) recently announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) and a Type II variation to the European Medicines Agency (EMEA) for marketing approval of Viread(R) (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B in adults. Viread is already approved in the United States and European Union for the treatment of HIV as part of combination antiretroviral therapy. The submissions contain data from two Phase III pivotal clinical trials, Studies 102 and 103, in patients chronically infected with the hepatitis B virus (HBV).
Drug developer NPS Pharmaceuticals Inc. (NASDAQ: NPSP) said recently its drug to treat short bowel syndrome failed to meet its goal in a late stage study. Short bowel syndrome is a condition where a person cannot properly absorb the nutrients from food. Symptoms include abdominal pain, diarrhea, weight loss, and malnutrition. The Phase III clinical trial compared either a low or high dose of the drug, called Gattex, with placebo. The goal of the study was a reduction in parenteral nutrition, or being fed intravenously, of at least 20 percent.
About U.S. Equity News
U.S. Equity News provides information, resources and news services for investors of small-cap, micro-cap and emerging companies. U.S. Equity News distributes RSS news feeds and a free subscription-based newsletter available through its website at www.usequitynews.com.
U.S. Equity News is a financial news distribution service by Equity Solutions, Inc. (www.equityirsolutions.com) that provides a platform for public companies to disseminate important news to key Wall Street interest such as shareholders and new investors. Equity Solutions, Inc. can assist by providing an effective increase in the awareness of a public company's news, development and corporate story through its proprietary network and its financial portal. U.S. Equity News and its affiliates charge each client cash for news distribution and may take an equity position in the companies mentioned herein, please visit the disclaimer at www.USEquityNews.com